Unless an ectopic pregnancy is visible by ultrasound, diagnosis can be a challenge. Differentiating ectopic pregnancies from intrauterine pregnancies can be impossible without intervention or follow-up. This poses a clinical dilemma to the practitioner given the inherent danger to the mother of tubal rupture of an ectopic pregnancy versus the fear of intervening in the case of a desired pregnancy without certainty of diagnosis. Early diagnostic modalities are clearly lacking, and serum biomarkers are currently being investigated as a solution to need for a rapid and accurate test for ectopic pregnancy.
Introduction
Ectopic pregnancy (EP) is a major cause of maternal morbidity and is responsible for pregnancy-related deaths in the first trimester. 1 Diagnosing an EP is a challenge to the clinician because there is no definitive nonsurgical diagnostic test when the diagnosis is unclear by routine blood tests and ultrasound, and diagnosis often requires following up patients over multiple visits. A rapid and accurate serum test to detect the presence of an EP would permit early treatments to prevent mortality and morbidity of this condition with preservation of fallopian tube function and fertility. 1 Currently, research is underway to both identify novel biomarkers and combine new and existing markers into a multiple marker test with the goal of accurately identifying ectopic pregnancies. The following discussion will describe the current use of biomarkers in clinical practice and the present state of serum biomarker research, including the markers being investigated and the methods which are being used to discover novel candidates.
Current Use of Serum Biomarkers for the Diagnosis of EP
A serum biomarker is a molecule, that an affected individual produces, that indicates the diseased state and is detectable in the serum. A biomarker for EP will ideally allow early diagnosis or predict prognosis. 2 Currently, the only biomarker used routinely in clinical practice is human chorionic gonadotropion (hCG), but it is not diagnostic and can only assist diagnosis in combination with ultrasound use. A single value is useful clinically in determining whether a gestational sac should reliably be visible on ultrasound (the ''discriminatory zone'') in an intrauterine pregnancy. Below this level, following serial hCG levels can help to distinguish a viable intrauterine pregnancy from an EP or nonviable intrauterine pregnancy. However, even observing serial levels has limitations in that the expected minimum rate of rise in 48 hours in a viable pregnancy varies in reports from 35% to 66%. 3 Given that 1 value of hCG below the discriminatory zone is nondiagnostic, clinicians must also follow up patients over several days to a week, which increases the risk of tubal rupture and life-threatening hemorrhage. 1 Despite its limitations, serial hCG levels in combination with transvaginal ultrasound is the most commonly used clinical method for determining which patients are at highest risk for EP and warrant surgical or medical treatment.
Progesterone has also been studied extensively and has been used in some clinical centers as an adjunct to transvaginal ultrasound and hCG levels. Early in pregnancy before placental production, progesterone is secreted by the corpus luteum and is a critical hormone for the establishment of normal pregnancy. 4 A systematic review of progesterone as a serum marker for EP found that a single value did have good discrimination for a nonviable pregnancy, and only 0.3% of patients with a viable intrauterine pregnancy in the combined studies had serum progesterone value <5 ng/mL. 5 However, a low value could not discriminate between a nonviable intrauterine pregnancy and an EP. 5 Further, in the studies examined, 2.6% of patients with a serum progesterone level >20 ng/mL had an EP, and high values do not definitively rule out an EP. 5 In summary, a low single serum progesterone level can aid in identifying patients at higher risk for an EP who need to be followed vigilantly, but a high value should be interpreted cautiously given the continued possibility of an EP.
Phases of Biomarker Research
Despite the important clinical need for biomarkers of EP, the currently used biomarkers are limited. Research is currently underway to identify and develop novel biomarkers, which may have improved diagnostic accuracy. This discovery process has distinct phases: (1) preclinical exploration to identify promising markers; (2) establishment of a clinical assay to be used on a larger scale; (3) testing the utility of the biomarker typically with a longitudinal or retrospective cohort; and (4) validation of the marker to determine its clinical value, usually in a prospective screening. 2, 6, 7 Although the preliminary stages have been pursued for the diagnosis of EP and are described in the following sections, no studies have progressed to phase IV.
Proposed Biomarkers for EP
A number of EP biomarkers have been proposed, although with limited validation (Table 1) . 3, 8, 9 Biomarkers have been evaluated based on the different biological functions theorized to be altered in the abnormal growth of an EP in the fallopian tube. These include (1) markers of abnormal trophoblast, corpus luteum, and endometrial function; (2) markers of implantation and growth in the fallopian Serum Biomarkers for Ectopic Pregnancy 419 tube, such as angiogenesis and muscle cell damage; and (3) inflammatory markers. Once a pregnancy is established, the rise of hCG produced by the trophoblasts is one indicator of the viability of the pregnancy. Trophoblasts also produce a number of other proteins, which have also been examined for the ability to differentiate normal versus abnormal pregnancies. Such proteins include activin A, pregnancy-specific b-1-glycoprotein (SP1), pregnancy-associated plasma protein-A (PAPP-A), and human placental lactogen. 3, [9] [10] [11] In addition, the corpus luteum is maintained in pregnancy by the trophoblast secretion of hCG, and normal corpus luteal function is necessary for the continued progression of pregnancy. Given the abnormal hCG dynamics of an EP, researchers have looked to an alteration in luteal proteins as a possible marker of EP, including not only progesterone, but inhibin A, estradiol, relaxin, and renin. 3, [9] [10] [11] Endometrial proteins, such as glycodelin, activin B, leukemia inhibitory factor, which are released into the maternal circulation with normal implantation have also been studied. 3, [9] [10] [11] As expected, these proteins that are involved in the normal implantation and progression of pregnancy are frequently found to be decreased in ectopic pregnancies, but as a single marker, they do not demonstrate consistently good discriminatory values. 3, [9] [10] [11] The markers which reflect the viability of a pregnancy may be higher in normal intrauterine pregnancies but may not differentiate an abnormal pregnancy in the uterus (miscarriage) versus an abnormal pregnancy in the fallopian tube (EP). Markers reflecting the location of the pregnancy, rather than viability, may therefore be able to differentiate between the 2 types of nonviable conceptuses: a miscarriage and an EP. One such marker is that of smooth muscle damage. As the EP grows and invades the muscular layer of the fallopian tube, it is possible that markers of muscle cell damage may also rise. Myoglobin and smooth muscle heavy-chain myosin have been studied but were found to be not useful in the screening for EP. 12 Creatine kinase has been studied extensively, and is often statistically elevated in ectopic pregnancies, especially if ruptured but with overall poor discriminatory values. 3, [9] [10] [11] In contrast to implantation in the well-vascularized endometrium, tubal implantation may involve other factors that are induced under hypoxic conditions and vascular endothelial growth factor (VEGF), a marker of angiogenesis, has also been examined. 13 There is increased expression of VEGF and its receptor at the implantation site of an EP, suggesting it may be involved in the implantation of the pregnancy in the fallopian tube. 14 
420
Rausch and Barnhart www.clinicalobgyn.com correlate with the depth of trophoblastic penetration into the wall of the oviduct. 13 Indeed, VEGF levels have been found to be elevated in EP, but as a single marker do not have adequate discrimination. 3, [9] [10] [11] Markers of inflammation and peritoneal irritation, such as interleukin-8, interleukin-6, tumor necrosis factor-a (TNF-a), CA-125, have also been investigated with conflicting results and no consistent proven utility for discrimination of EP. 3, [9] [10] [11] 
Biomarkers Used in Combination
Given the ramifications of a false positive or negative test, namely interruption of a desired, normal pregnancy, or serious morbidity and possibly mortality, respectively, only a test with superior sensitivity and specificity would be clinically applicable. As none of the currently discovered biomarkers has consistently differentiated ectopic pregnancies, several researchers have attempted to combine several markers into 1 test with better diagnostics than individual proteins ( Table 2 ).
The combination of inflammatory cytokines interleukin (IL)-6, IL-8, and TNF-a was able to predict EP with specificity of 100%, but sensitivity of 52.9%. 15 Combining markers with multiple biological functions has proven more successful. One group in Switzerland developed a multiple marker test, the ''triple marker analysis'' [VEGF/(PAPP-A X P)] had a sensitivity of 97.7% with a specificity of 92.4% in diagnosing EP. 16 More recently, 12 markers previously associated in the literature with EP that spanned a number of possible mechanisms were assessed individually and in combination. As single markers, inhibin A, progesterone, activin A, VEGF, SP1, and PAPP-A were differentially expressed in patients with EP and intrauterine pregnancy (P<0.0001) with fair diagnostic properties (area under the receiver operating characteristic curves >0.6). TNF-a, IL-6, IL-8, glycodelin, creatine kinase, and human placental lactogen had limited value. 9 A diagnostic algorithm was developed to maximize both sensitivity and specificity with 4 markers (progesterone, VEGF, inhibin A, activin A), which achieved 100% specificity and 98% (93% to 100%) sensitivity, only in those that could be characterized (42% of the sample). 9 Overall, a single EP was misclassified, which corresponds with 99% (96% to 100%) accuracy. 9 Of interest was that these models demonstrated perfect discrimination in the subgroup of patients where ultrasound is usually nondiagnostic. 9 Although they demonstrate promising results, such multiple marker tests need external validation before they can be put into practice.
Discovery of Novel Biomarkers
Testing for differences between normal and abnormal pregnancy based on a hypothesis that any 1 maker may be beneficial is the traditional method to search for new markers. More recently, genomics 17, 18 and proteomics 19, 20 have been used for a more unbiased approach to biomarker discovery. Quantitatively comparing the proteome of biological fluids such as serum 16 [VEGF/(PAPP-A X P)] 97.7% 92.4% Rausch et al 9 Progesterone, VEGF, inhibin A, activin A 98% 100%* *Only in those that could be characterized (42% of the sample). IL indicates interleukin; TNF-a, tumor necrosis factor-a; VEGF, vascular endothelial growth factor.
Serum Biomarkers for Ectopic Pregnancy 421 from patients and normal controls has great potential for detecting novel biomarkers not dependent on the imagination and hypotheses of the researchers. However, such studies are very challenging due to the high complexity of the serum proteomes, a wide protein abundance range with very low concentrations of most clinically useful biomarkers, patient-to-patient variability, and potential variations in sample collection and processing. A recent study that screened the proteome of a small group of women with EP and controls reidentified several proteins previously associated with EP with either high (choriogonadotropin subunit beta precursor and glycoprotein hormones alpha chain precursor) or low (PAPP-A, chorionic somatomammotropin hormone precursor 1, and progestagen-associated endometrial protein) significance, confirming their possible use as biomarkers for EP. 19 However, this unbiased approach also discovered potential novel biomarkers, including ADAM-12 and ISM2 (isthmin 2) as well as 5 specific isoforms of the SP1 family multiple proteins. 19 One of the most promising, novel candidate biomarkers was ADAM-12 (a disintegrin and metalloprotease-12). It was selected for further validation testing in a larger group of 199 patients using a commercial dissociation-enhanced lanthanide fluoroimmunoassay, which showed significantly lower levels of ADAM-12 in the EP group (mean 11.7 ng/mL ± 48.2) compared with the intrauterine pregnancy group (mean 115.4 ng/mL ± 214.1; P<0.0001) with good discrimination between the groups (area under the receiver operating characteristic curves = 0.82). 21 The discoveries of novel biomarkers, such as these, may improve the diagnostic ability of existing multiple marker tests even if they do not have sufficient diagnostic capability as single markers.
Future Directions
Given the present lack of a clinically useful test for the accurate diagnosis of EP, there are several goals for future biomarker research if a robust and validated test is to be obtained. Identifying novel candidates through unbiased techniques is currently underway, and as the list of potential candidates grows such biomarkers need to be triaged to select out those with the most promise. Multiple marker tests, which can take advantage of different biological mechanisms of a panel of biomarkers rather than a single protein, will more likely be able to differentiate among normal and abnormal pregnancies. The final key step is the validation of candidates in independent cohorts, which is lacking in all of the studies up to date. Further, the best clinical use of such a test needs to be clearly defined and honed as they are being developed. For instance, should such tests be optimized for detecting EP from intrauterine pregnancies, distinguishing a nonviable pregnancy (EP or miscarriage) from a normal, viable pregnancy, or assist in prognosis (determine the most threatening pregnancies at risk of rupture). A test developed with any of these goals could be of significant assistance to clinicians in deciding how to triage and treat their patients.
